filmov
tv
Combination Trials in Advanced Bladder Cancer
Показать описание
Panelists Daniel P. Petrylak, MD; Elizabeth R. Plimack, MD, MS; and Arjun V. Balar, MD, provide insight on the DANUBE trial, which looks at combining the PD-L1 inhibitor, durvalumab, with the CTLA4 inhibitor, tremelimumab, in patients with advanced bladder cancer, and discuss immunotherapy in the localized setting with chemotherapy and radiotherapy.
0:05:14
0:07:47
0:15:53
0:15:30
0:21:20
0:01:04
0:02:47
0:25:10
0:01:14
0:10:44
0:03:15
0:00:55
0:06:01
0:02:26
0:08:24
0:01:14
0:01:17
0:02:26
0:00:58
0:03:30
0:00:51
0:01:32
0:16:22
0:08:03